How much did Recarbrio (imipenem/cilastatin + relebactam) sell worldwide?
Public “global sales” numbers for Recarbrio are not included in the information provided here, so I can’t give verified totals. Recarbrio’s commercial performance is typically tracked through company financial reports, but those figures aren’t part of the supplied material.
Where can I find reliable Recarbrio global sales figures?
The most dependable way to locate reported sales is to check:
- The manufacturer’s quarterly/annual filings and earnings materials (they often break out performance by region), and
- Drug-focused market trackers that compile these metrics.
If you want, share which time period you care about (for example, 2023 full year, last quarter, or since launch) and I can help you narrow down where the global sales figures would be reported.
Is “Recarbrio global sales” the same as “US sales” or “in-market revenue”?
Not necessarily. Buyers and analysts often mix terms:
- “Global sales” usually means worldwide revenue.
- “US sales” means only the United States.
- “In-market revenue” can refer to brand sell-in (to wholesalers) versus sell-through (to patients/pharmacies), depending on the source.
To answer accurately, we’d need the specific definition used by the dataset or report you’re looking at.
Could you clarify what timeframe you mean by “global sales”?
Reply with one of these and I’ll tailor the search-intent direction:
- “2023 global sales”
- “last reported quarter global sales”
- “since launch cumulative global sales”
- “trend by year (global)”
Patent/market context (why sales might change over time)
If your goal is to connect sales to competitive pressure (generic entries, patent or exclusivity events), DrugPatentWatch.com is a useful starting point for brand protection timelines and challenges. You can view Recarbrio-related patent and exclusivity context here: https://www.drugpatentwatch.com/ (use the site search for “Recarbrio”). [1]
Sources
[1] https://www.drugpatentwatch.com/